Tangier disease

Jump to navigation Jump to search

Lipid Disorders Main Page

Overview

Causes

Classification

Abetalipoproteinemia
Hypobetalipoproteinemia
Familial hypoalphalipoproteinemia
LCAT Deficiency
Chylomicron retention disease
Tangier disease
Familial combined hypolipidemia

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2], Twinkle Singh, M.B.B.S. [3] Aravind Kuchkuntla, M.B.B.S[4]

Synonyms and keywords: Familial alphalipoprotein deficiency, HDL deficiency - familial, high density lipoprotein deficiency, analphalipoproteinaemia, high density lipoprotein deficiency - type 1, high density lipoprotein deficiency - Tangier type, A-alphalipoprotein Neuropathy, alpha High Density Lipoprotein Deficiency Disease, Cholesterol thesaurismosis, Familial Hypoalphalipoproteinemia, Tangier Disease Neuropathy, Tangier Hereditary Neuropathy


Overview

Tangier is a disease due to a mutation in HDL C levels..It is characterized by low or absent HDL, Apo A1 and accumalation of Cholesterol esters in tonsil, peripheral nerves, liver, skin and cornea. Low HDL is an independent cardiovascular risk factor.

Historical perspective

  • In 1960, Fredricson and colleagues described the disease in two young siblings from Tangier Island in the Chesapeake Bay. They described the condition to have very low plasma levels of HDL C, moderately elevated triglycerides and decreased LDL cholesterol levels. The patients presented with mild corneal opacification, hepatosplenomegaly and orange coloured tonsils. Cholesterol- laden macrophages were found in their tonsils, bone marrow, nerves and smooth muscle cells.
  • In 1985, Francis and Oram and also Schmitz and Assmann, noted that TD is a disorder of intacellular membrane traffic.[1]
  • In 1998, the chromosomal locus (9q31) for TD was identified by Rust and Assmann. [2]
  • In 1999, Genomic organization and the genetic defect was identified.[3]
  • In 1999, the function of the ABCA1 transporter in the efflux of cellular cholesterol as phospholipid to HDL and ApoA-I was reported.[4].
  • In later part of 1999, three different research groups reported different mutations in ABCA1 as causes of homozygous Tangier disease.[5][6]
  • In 2000, three different research groups confirmed that mutation in ABCA gene could cause Tangier disease.[7]

Classification

  • Homozygous and heterozygous Tangier disease.

Pathophysiology

Pathogenesis

  • Gene involved in the pathogenesis of TD include ATP-Binding Cassette tansporter gene(ABCA10, on chromosome 9q31. [8], which mediates the secretion of cellular free cholesterol and phospholipids to an extracellular acceptor, apolipoprotein AI, to form nascent high-density lipoprotein (HDL). .[9]
  • Mutation affects the the efflux of cholesterol from the cells, first step of reverse cholesterol transport, which leads to accumulation of cholesterol esters in the cells. The failure of lipidation of Apo-A1 results in rapid catabolism of Apo A1 in the kidney which eventually causes very low Apo-A1 levels.[10]
  • HDL C complexity.[11]

Genetics

  • Autosomal recessive inheritance.
  • Multiple mutation sites are identified.

Reverse cholesterol transport

 
 
 
Very small discoidal Pre beta HDL picks up free cholesterol from cells via ABCA1 converting small discoidal pre beta HDL to small discoidal alpha4 HDL, this intitial step is disrupted in Tangier disease causing to have only pre beta HDL on 2D electrophoresis.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Then LCAT converts small discoidal α-4 HDL to larger spherical alpha HDL converting free cholesterol into cholesterol esters (CE). Lipoprotien lipase is also required for this step
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Larger alpha HDL can donate the CE to TG-rich lipoproteins (TRL) in exchange for TG via the action of CE transfer protein (CETP) or
 
 
 
Larger alpha HDL can donate the CE and free cholesterol to the liver via scavenger receptor-B1 (SR-B1)
  • Studies show that during the above process Apo A1 can be recycled back to the discoidal HDL or be catabolized in the kidney by the action of the enzyme cubulin.
  • Studies also show that hepatic and endothelial lipase helps remove the phospholipid from large HDL to convert it into small HDL.

Microscopic pathology

Associated Conditions

Demographics, Natural History and Complications

  • Tangier disease has been diagnosed in about 100 patients in many countries.[17]
  • Cardiovascular disease risk is increased particularly in homozygotes and elderly patients with Tangier disease. Deposition of lipid filled macrophages in arterial wall results in accelerated atherosclerosis.[18]

Diagnosis

History and Symtoms

  • The characteristic clinical presentation of TD include
    • Tonsil enlargement in children.
    • Symptoms of peripheral neuropathy in adults.
    • Other less common features of presentation include abdominal discomfort due to hepatomegaly, splenomegaly, visual disturbances due to corneal haziness and premature myocardial infarction or stroke.

Physical Exam

  • Large yellow-orange tonsils.
  • Corneal opacity.
  • Loss of neurons and lipid accumulation in Schwann cells result in neuropathy. Two patterns of neuropathy have been noticed:
    • Syringomyelia type loss of sensory and motor neurons in upper body.[19]
    • Peripheral neuropathy with fluctuating loss of sensory and motor function.[20]
  • Splenomegaly and hepatomegaly from accumulation of cholesterol esters in reticuloendothelial cells.

Laboratory Findings

Characteristic lab findings include:

  • Plasma HDL cholesterol is very low or totally absent (usually below 5 mg/dL).
  • Plasma total cholesterol is low (below 150 mg/dL).
  • Triglyceride plasma levels are normal or elevated (up to 400 mg/dL).
  • Serum concentrations of apoA-I and apoA-II lipo- proteins are below 5 mg/dL.
  • Other laboratory findings include thrombocytopenia and stomatocytosis.

Genetic Testing

Gold standard for diagnosis: ABCA1 gene sequence analysis.

Others

Prebeta 1-HDL is identified on 2D electrophoresis after anti-apo A1 immunoblotting.[21]

Treatment

Medical Therapy

Surgical therapy

References

  1. ↑ Schmitz G, Assmann G, Robenek H, Brennhausen B (1985). "Tangier disease: a disorder of intracellular membrane traffic". Proc Natl Acad Sci U S A. 82 (18): 6305–9. PMC 391042. PMID 2994070.
  2. ↑ Rust S, Walter M, Funke H, von Eckardstein A, Cullen P, Kroes HY; et al. (1998). "Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy". Nat Genet. 20 (1): 96–8. doi:10.1038/1770. PMID 9731541.
  3. ↑ Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C; et al. (1999). "Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred". Proc Natl Acad Sci U S A. 96 (22): 12685–90. PMC 23050. PMID 10535983.
  4. ↑ Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G; et al. (1999). "Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages". Biochem Biophys Res Commun. 257 (1): 29–33. doi:10.1006/bbrc.1999.0406. PMID 10092505.
  5. ↑ Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M; et al. (1999). "Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency". Nat Genet. 22 (4): 336–45. doi:10.1038/11905. PMID 10431236.
  6. ↑ Bodzioch M, Orsó E, Klucken J, Langmann T, Böttcher A, Diederich W; et al. (1999). "The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease". Nat Genet. 22 (4): 347–51. doi:10.1038/11914. PMID 10431237.
  7. ↑ Brousseau ME, Schaefer EJ, Dupuis J, Eustace B, Van Eerdewegh P, Goldkamp AL; et al. (2000). "Novel mutations in the gene encoding ATP-binding cassette 1 in four tangier disease kindreds". J Lipid Res. 41 (3): 433–41. PMID 10706591.
  8. ↑ Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC; et al. (1999). "Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1". Nat Genet. 22 (4): 352–5. doi:10.1038/11921. PMID 10431238.
  9. ↑ Wang S, Smith JD (2014). "ABCA1 and nascent HDL biogenesis". Biofactors. 40 (6): 547–54. doi:10.1002/biof.1187. PMC 4294467. PMID 25359426.
  10. ↑ Emmerich J, Vergès B, Tauveron I, Rader D, Santamarina-Fojo S, Shaefer J; et al. (1993). "Familial HDL deficiency due to marked hypercatabolism of normal apoA-I". Arterioscler Thromb. 13 (9): 1299–306. PMID 8364014.
  11. ↑ Asztalos BF, Tani M, Schaefer EJ (2011). "Metabolic and functional relevance of HDL subspecies". Curr Opin Lipidol. 22 (3): 176–85. doi:10.1097/MOL.0b013e3283468061. PMID 21537175.
  12. ↑ Ferrans VJ, Fredrickson DS (1975). "The pathology of Tangier disease. A light and electron microscopic study". Am J Pathol. 78 (1): 101–58. PMC 1915033. PMID 162820.
  13. ↑ Reinhart WH, Gössi U, Bütikofer P, Ott P, Sigrist H, Schatzmann HJ; et al. (1989). "Haemolytic anaemia in analpha-lipoproteinaemia (Tangier disease): morphological, biochemical, and biophysical properties of the red blood cell". Br J Haematol. 72 (2): 272–7. PMID 2757970.
  14. ↑ Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R; et al. (2009). "Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations". J Atheroscler Thromb. 16 (3): 292–6. PMID 19556721.
  15. ↑ Sampietro T, Puntoni M, Bigazzi F, Pennato B, Sbrana F, Dal Pino B; et al. (2009). "Images in cardiovascular medicine. Tangier disease in severely progressive coronary and peripheral artery disease". Circulation. 119 (20): 2741–2. doi:10.1161/CIRCULATIONAHA.108.812164. PMID 19470903.
  16. ↑ Hooper AJ, Robertson K, Ng L, Kattampallil JS, Latchem D, Willsher PC; et al. (2009). "A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency". Clin Chim Acta. 409 (1–2): 136–9. doi:10.1016/j.cca.2009.08.017. PMID 19723515.
  17. ↑ Puntoni M, Sbrana F, Bigazzi F, Sampietro T (2012). "Tangier disease: epidemiology, pathophysiology, and management". Am J Cardiovasc Drugs. 12 (5): 303–11. doi:10.2165/11634140-000000000-00000. PMID 22913675.
  18. ↑ Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED; et al. (1994). "Homozygous Tangier disease and cardiovascular disease". Atherosclerosis. 107 (1): 85–98. PMID 7945562.
  19. ↑ Gibbels, E.; Schaefer, HE.; Runne, U.; Schröder, JM.; Haupt, WF.; Assmann, G. (1985). "Severe polyneuropathy in Tangier disease mimicking syringomyelia or leprosy. Clinical, biochemical, electrophysiological, and morphological evaluation, including electron microscopy of nerve, muscle, and skin biopsies". J Neurol. 232 (5): 283–94. PMID 2997405.
  20. ↑ Pietrini, V.; Rizzuto, N.; Vergani, C.; Zen, F.; Ferro Milone, F. (1985). "Neuropathy in Tangier disease: A clinicopathologic study and a review of the literature". Acta Neurol Scand. 72 (5): 495–505. PMID 4082916. Unknown parameter |month= ignored (help)
  21. ↑ Huang Y, von Eckardstein A, Wu S, Langer C, Assmann G (1995). "Generation of pre-beta 1-HDL and conversion into alpha-HDL. Evidence for disturbed HDL conversion in Tangier disease". Arterioscler Thromb Vasc Biol. 15 (10): 1746–54. PMID 7583552.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Tangier_disease&oldid=1268201"